by Clinical Neuropsychologist Online | Monday, July 20, 2026 | Dementia
Abstract INTRODUCTION Although cerebrospinal fluid (CSF) biomarkers reflect neurodegeneration in Alzheimer’s disease (AD), it remains unclear whether these biomarkers track neurodegeneration in early-onset Alzheimer’s disease (EOAD). METHODS In 80 EOAD...
by Clinical Neuropsychologist Online | Monday, July 20, 2026 | Dementia
Abstract People with dementia are at increased risk of hospitalization compared to individuals without dementia, yet the efficacy of psychosocial and healthcare interventions in reducing hospitalization is unclear. We conducted an umbrella review examining the effects...
by Clinical Neuropsychologist Online | Monday, July 20, 2026 | Dementia
Abstract Evidence linking sleep and circadian disruptions to the course of dementias, particularly Alzheimer’s disease, has expanded. Such alterations are detectable from preclinical stages and parallel the disease progression. Assessing and managing sleep and...
by Clinical Neuropsychologist Online | Sunday, July 19, 2026 | Dementia
Abstract INTRODUCTION Neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), limbic-predominant age-related TDP-43 encephalopathy (LATE), and Alzheimer’s disease (AD) are associated with TAR DNA-binding protein...
by Clinical Neuropsychologist Online | Sunday, July 19, 2026 | Dementia
Abstract INTRODUCTION The National Institute on Aging-funded IMbedded Pragmatic Alzheimer’s disease and AD-Related Dementias Clinical Trials (IMPACT) Collaboratory was established to build capacity for conducting embedded pragmatic clinical trials (ePCTs) within...
